Pressing into Phase III

Three small companies last week moved products into Phase III testing: Aeterna Laboratories Inc.'s Neovastat (AE-941) angiogenesis inhibitor to treat renal cell carcinoma, Cellegy Pharmaceuticals Inc.'s Anogesic nitroglycerin to treat chronic anal fissures and Genta Inc.'s G3139 antisense agent against Bcl-2 to treat malignant melanoma. However, based on experience to date with the compounds, it is not clear how much risk has been taken out prior to Phase III.

In CLGY's previous 304-patient Phase III trial, Anogesic failed to meet

Read the full 794 word article

How to gain access

Continue reading with a
two-week free trial.